The same studies indicated that 5-AZA-CdR treatment (DNA methyltransferase inhibitor) significantly increased miR-335 expression, which later influences the HGF/c-Met pathway, and, simultaneously, the level of miR-335 that can play a significant role in breast cancer diagnosis and prognosis and novel strategies for BC therapy [107,108,109]. The gene discussed is MET; the disease is breast cancer.